PMG-1015
/ Pulmongene
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 24, 2025
Safety, Tolerability, and Clinical Pharmacology of PMG1015: An Anti-Amphiregulin Antibody as a Novel Treatment for Idiopathic Pulmonary Fibrosis
(ATS 2025)
- P1a | "PMG1015 is safe and well-tolerated with favorable pharmacokinetic characteristics in healthy volunteers. These results support the progression of PMG1015 to further studies in patients with IPF."
Clinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
June 08, 2023
A Study of PMG1015 Injection in Idiopathic Pulmonary Fibrosis Subjects
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Pulmongene Ltd.
New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • MB
December 08, 2022
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015
(clinicaltrials.gov)
- P1a | N=54 | Completed | Sponsor: Pulmongene Ltd. | Recruiting ➔ Completed
Trial completion • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1